AT A GLANCE
- X-Injector
- Automated multi-needle delivery platform
- Hand injection
- Point-by-point clinician control
- Evidence limit
- No exact-device superiority trial found
- Travel rule
- Leave time for recovery and review
The short answer: the device changes delivery—not the ingredient
X-Injector is an automated multi-needle platform that can help deliver a selected product at planned depth and volume settings. Hand injection lets the clinician change angle, depth, entry point and aliquot point by point. Neither method determines whether the chosen skin booster is appropriate, and neither guarantees less pain, fewer papules or faster recovery.
Le Moir Clinic currently offers X-Injector and describes it as a delivery platform rather than a skin booster. That distinction matters: REJURAN, hyaluronic-acid gels, PDLLA products and human dermal-matrix products have different formulations, instructions, evidence and risks even if the same device can physically hold a syringe.
A useful consultation therefore starts with the exact sealed product and concern, then asks whether automated or manual delivery fits the area. The answer may differ across the forehead, cheeks, under-eye region or scars—and it may be to postpone injection during a short trip.
What X-Injector can standardize—and what it cannot decide
The manufacturer identifies X-Injector as an electric infusion pump used to inject a set amount of liquid, with a multi-needle component. Le Moir's current equipment page describes planned depth and volume as its practical role. Those descriptions support a discussion about repeatable settings; they do not prove that every droplet reaches an identical tissue plane in every face.
Skin thickness, curvature, contact, pressure, needle length, tissue movement and the viscosity of the selected product can all affect delivery. A 2024 laboratory study using porcine skin found that syringe diameter, needle diameter and length, and product viscosity changed the force required for intradermal injection. It did not test X-Injector or establish a superior cosmetic result.
The device also cannot diagnose whether the concern is dehydration, active dermatitis, acne, pigment, scarring, volume loss or laxity. It cannot choose the product, rule out contraindications, sterilize poor technique or replace a clinician's anatomical judgment and follow-up plan.
- Ask for the exact product, original volume, final volume and any dilution or mixing.
- Ask which needle set, depth, aliquot and treatment area are planned.
- Ask what the clinician changes manually when the face is curved or the tissue is thin.
- Keep the product label, lot, treatment map and urgent-contact route after the visit.
Why hand injection may still be chosen for some areas
Manual injection is not simply an older version of automated delivery. It can let an experienced clinician alter the angle, plane, spacing and amount for a small or anatomically complex zone. An automated multi-needle platform may be discussed when a broader area and more uniform pattern are desired. A cannula can represent another technique, but it is not automatically safer and may place product in a different plane.
Published depth research shows why technique claims deserve care. A 2018 analysis reported that many injections described as intradermal were actually calculated to reach the fat layer. A separate cadaver and ultrasound study found that needle length and insertion angle changed whether a PN product was placed in the dermis or just beneath it. These studies illustrate variables; they do not rank X-Injector against a skilled hand injector.
We did not find a peer-reviewed head-to-head trial of the exact X-Injector device versus hand injection that proves one method produces better skin quality, less pain or shorter downtime. If a clinic presents one method as universally superior, ask to see evidence for the exact product, area and outcome being promised.

Papules, bruising and pain: do not promise a device shortcut
Temporary raised injection points, redness, swelling, tenderness and bruising can occur after a skin-booster procedure. Their visibility depends on the product, plane, aliquot, number of punctures, suction or contact, treatment area, individual response and aftercare. A device setting cannot provide a universal photo-ready deadline.
Pain is also not determined by the machine name. Needle count, treatment area, product viscosity, injection pressure, entry points, speed, local anesthesia and personal sensitivity all matter. Ask how comfort will be managed without assuming that automated delivery is painless or that hand injection must hurt more.
The product-specific instructions remain central. Expected reactions and rare complications differ across PN, HA, PDLLA and other materials. The treating clinician should explain what is expected for the named product and method, what is not expected and when an in-person examination is needed.
Plan around the flight home, not a fixed downtime number
There is no credible rule that X-Injector makes a visitor safe to fly the same day or guarantees that papules will settle before an event. Flying does not itself convert every minor injection reaction into an emergency, but a tightly timed departure can remove the opportunity for the treating clinic to examine pain, swelling, discoloration or another unexpected change.
Share your arrival, event and departure dates before booking. Leave practical time for recovery and an in-person review, especially if this is your first treatment with the product or delivery method. Obtain written aftercare in English and confirm how the clinic can communicate with a doctor at home if needed.
Seek prompt medical assessment for severe or increasing pain, blanching or unusual mottled color, vision change, weakness, fever, spreading redness, pus or rapidly worsening swelling. Do not rely on social media or a flight schedule when symptoms are escalating.
A fair quote names both the product and the delivery plan
An X-Injector surcharge and a skin-booster price are not the same unit. A useful written quote names the product, original syringe or vial amount, any final mixed volume, device or manual technique, needle set, treatment area, clinician, anesthesia, VAT, aftercare and review.
We did not verify a standardized device-only price in the United States or Europe that matches Le Moir's exact product, needle setup, area and follow-up. This guide therefore makes no overseas savings claim and shows no currency conversion. Compare written plans only when those details are substantially the same.
If the clinic cannot explain why X-Injector or hand injection is being proposed for your product and anatomy, pause. A considerate plan can include a different method, a smaller area, a later appointment, consultation only or no injection on this trip.
PRICE CONTEXT · SEPTEMBER 2026
What a fair comparison includes
Delivery-method pricing is meaningful only when the exact product, original and final volume, needle setup, area, clinician, anesthesia, VAT, aftercare and follow-up are matched. We did not verify a like-for-like international pair.
| Market | Price | Comparison basis |
|---|---|---|
| United States | No matched public device-only price | No verified plan matched the X-Injector device, named product, volume, area, needle setup, tax and review |
| Europe | No matched public device-only price | Public skin-booster quotes did not hold the delivery platform, product, volume, area and follow-up constant |
| Le Moir Clinic · Seoul | Current written quote required | Confirm the product and any separate X-Injector or manual-delivery fee after physician assessment |
No currency conversion is shown because no like-for-like public price pair was verified. If you later compare written quotes, use the European Central Bank's dated reference rates and keep the product, amount, delivery method, area, tax and follow-up basis constant ECB reference rates.
No Korea-versus-overseas savings claim is made. A low headline price may omit the product amount, dilution, delivery method, anesthesia, VAT or review. Ask for one itemized written plan before comparing.
COMMON QUESTIONS
Before you book
Is X-Injector a skin booster?
No. X-Injector is a delivery platform. The injected product—such as PN, HA, PDLLA or another material—has its own formulation, intended use, evidence and risks and must be chosen separately after assessment.
Is X-Injector better than hand injection?
Not universally. Automated delivery can help apply planned settings across a broader pattern; hand injection can give point-by-point control for a curved or small area. We found no exact-device head-to-head trial proving one method gives better results or less downtime for everyone.
Does X-Injector hurt less or cause fewer papules?
That cannot be guaranteed from the device name. Product viscosity, depth, aliquot, puncture count, treatment area, injection pressure, anesthesia and individual sensitivity all affect pain and visible recovery.
Can I fly after an X-Injector skin-booster treatment?
There is no universal device-specific clearance time. Share your flight date before treatment, leave time for recovery and an in-person review, and obtain written aftercare. Worsening pain, unusual color change, vision symptoms, fever or spreading redness needs prompt medical assessment.
What should an X-Injector quote include?
It should name the exact product, original and final volume, any mixing, needle set, depth and aliquot plan, treatment area, clinician, anesthesia, VAT, aftercare, review and urgent-contact route. The device name and total price alone are not enough.
SOURCES & FURTHER READING
Check the original information
- Le Moir Clinic — official X-Injector treatment overview
- SKINX — official X-Injector device information
- PubMed — injection depth in intradermal therapy
- PubMed — 2024 skin-booster injection mechanics study
- PubMed Central — cadaver and ultrasound study of needle length and PN injection depth
- PubMed Central — 2026 review of intradermal and subdermal skin-booster targeting
- CDC Yellow Book — continuity and follow-up for medical tourism
Published September 21, 2026 · Last reviewed for factual accuracy September 21, 2026. Product availability, regulation and clinic pricing can change.



